+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are studying people in Asia and the United States who have chronic kidney disease CKD along with type 2 diabetes T2D to understand more about the use, safety, and effectiveness of the treatment finerenone in real-world settings. CKD is a long-term condition where the kidneys progressively lose function, and T2D is a condition where the body does not produce or use insulin properly, leading to high blood sugar that can damage the kidneys. Finerenone blocks certain proteins called mineralocorticoid receptors, which may help protect the kidneys, heart, and blood vessels. It was recently approved for use in the US, and this observational study aims to collect information on people receiving finerenone as part of their regular care. The study uses data from commercial electronic health records and national claims databases in Asia and the US, covering the period from July 1, 2021, to the most recent available data. Participants are adults with CKD and T2D who have started finerenone treatment prescribed by their doctors. Since this is an observational study, no new treatments or interventions are given by the researchers. Instead, the study collects existing data on participants, including their kidney function, heart health, other medical conditions, and medications used while on finerenone. Participants are not required to attend any study visits or tests specifically for this research. The researchers use already available health records to analyze participant characteristics, comorbidities, and medication use before and after starting finerenone. They also monitor outcomes such as kidney failure, cardiovascular events, and medication dosing over time. The study will continue until September 30, 2026, gathering long-term real-world information about finerenone use and safety in people with CKD and T2D.

Age: 18Years +All Genders
4 locations
M

Actively Recruiting

Researchers are conducting a pre-screening study to identify individuals who may qualify for Roche interventional studies focused on Alzheimers disease. This study aims to assess potential eligibility by evaluating specific biomarkers and cognitive performance, helping to select suitable participants for future clinical trials related to Alzheimers disease. Participants will undergo testing to measure the concentration of pTau217 in their blood and complete the International Shopping List Test ISLT to assess cognitive function. There is no active treatment or intervention instead, the study collects these measurements to determine potential trial eligibility. During the study, participants will have blood samples drawn and complete cognitive assessments using the ISLT. Researchers will focus on the pTau217 biomarker levels and cognitive scores as primary outcomes measured on the first day of participation. This screening process helps identify candidates for subsequent interventional Alzheimers disease trials. The study is planned to run until July 2035 and includes adults aged 50 to 90 years.

Age: 50Years - 90YearsAll GendersPhase 3
234 locations